Overexpression of Platelet-derived Growth Factor-D as a Poor Prognosticator in Endometrial Cancer |
Ding, Jie
(Department of Obstetrics and Gynecology, Third Affiliated Hospital, Sun Yat-sen University)
Li, Xiao-Mao (Department of Obstetrics and Gynecology, Third Affiliated Hospital, Sun Yat-sen University) Liu, Sui-Ling (Department of Obstetrics and Gynecology, Third Affiliated Hospital, Sun Yat-sen University) Zhang, Yu (Department of Obstetrics and Gynecology, Third Affiliated Hospital, Sun Yat-sen University) Li, Tian (Department of Obstetrics and Gynecology, Third Affiliated Hospital, Sun Yat-sen University) |
1 | Wang HL, Ren YF, Yang J, et al (2013).Total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 2515-9. 과학기술학회마을 DOI ScienceOn |
2 | Engelsen IB, Stefansson IM, Akslen LA, et al (2008). GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol, 199, 541-7. |
3 | Aas T, Borresen AL, Geisler S, et al (1996). Specific P53 mutations are associated with denovo resistance to doxorubicin in breast cancer patients. Nat Med, 2, 811-4. DOI ScienceOn |
4 | Deuel TF (1987). Polypeptide growth factors: roles in normal and abnormal cell growth. Annu Rev Cell Biol, 3, 443-92. DOI ScienceOn |
5 | Hwang RF, Yokoi K, Bucana CD, et al (2003). Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res, 9, 6534-44. |
6 | Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. DOI |
7 | Kong D, Banerjee S, Huang W, et al (2008). Mammalian target of rapamycin repression by3,3’-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D over-expressing PC3 cells. Cancer Res, 68, 1927-34. DOI ScienceOn |
8 | LaRochelle WJ, Jeffers M, Corvalan JR, et al (2002). Platelet derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer. Cancer Res, 62, 2468-73. |
9 | Wang ZW, Kong DJ, Li YW, et al (2009). PDGF-D signaling: a novel target in cancer therapy. Curr Drug Targets, 10, 38-41. DOI ScienceOn |
10 | Xu L, Tong R, Cochran DM, et al (2005). Blocking platelet derived growth factor-D/platelet-derived growth factor receptor signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res, 65, 5711-9. DOI ScienceOn |
11 | Yu J, Ustach C, Kim HR (2003). Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol, 36, 49-59. DOI |
12 | Wang XW, Zhong TY, Xiong YH, et al (2012). Lack of association between the ,CYP1A1 Ile462Val polymorphism and endometrial cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 13, 3717-21. 과학기술학회마을 DOI |
13 | Wang ZW, Ahmad A, Li YW, et al (2010). Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta, 1806, 122-30. |
14 | Wang ZW, Kong DJ, Banerjee S, et al (2007). Down-regulation of platelet derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and Nuclear Factor-B Signaling. Cancer Res, 67, 11377-85. DOI ScienceOn |
15 | Xiao L, Yang YB, Li XM, et al (2010). Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy. J Cancer Res Clin Oncol, 136, 1089-99. DOI |
16 | Mannelqvist M, Stefansson IM, Salvesen HB, et al (2009). Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology, 54, 174-83. DOI |
17 | Lokker NA, Sullivan CM, Hollenbach SJ, et al (2002). Plateletderived growth factor autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res, 62, 3729-35. |
18 | Xu C, Li X, Li T, et al (2011). Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells. Asian Pac J Cancer Prev, 12, 2951-7. |
19 | Stefansson IM, Salvesen HB, Akslen LA (2006). Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res, 66, 3303-9. DOI |
20 | Mannelqvist M, Stefansson IM, Bredholt G, et al (2010). Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol, 178, 861-71. |
21 | Rosenkranz S, Kazlauskas A (1999). Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors, 16, 201-16. DOI ScienceOn |
22 | Stefansson IM, Salvesen HB, Immervoll H, et al (2004). Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology, 44, 472-9. DOI |
23 | Ustach CV, Kim HR (2005). Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol, 25, 6279-88. DOI ScienceOn |
24 | Ustach CV, Taube ME, Hurst NJ, et al (2004). A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res, 64, 1722-9. DOI |
25 | Wan J, Li X (2012). PELP1/MNAR suppression inhibits proliferation and metastasis of endometrial carcinoma cells. Oncology Reports, 12, 2035-42. |
26 | Creasman WT, Morrow CP, Bundy BN, et al (1987). Surgical pathologic spread patterns of endometrial cancer. Cancer, 60, 2035-41. DOI |